HALLUCINOGEN USE DISORDER

SCF-RDOS INDICATION REGISTRY ENTRY

Classification

DEFINITION

HALLUCINOGEN USE DISORDER is a substance-use disorder characterized by a problematic pattern of hallucinogen consumption leading to clinically significant impairment, distress, loss of control over use, persistent craving, continued use despite adverse consequences, and disruption of psychological, social, occupational, or educational functioning.

Hallucinogens include substances capable of altering perception, cognition, mood, consciousness, and sensory processing. Examples include psychedelic compounds, dissociative hallucinogens, and naturally occurring psychoactive substances.

The defining feature is not the occurrence of perceptual alterations alone, but the maladaptive pattern of use, compulsive drug-seeking behavior, impaired functioning, and inability to reduce or control consumption despite negative consequences.

Within the SCF-RDOS framework, Hallucinogen Use Disorder is conceptualized as a substance-dependence syndrome involving dysregulation across reward-processing networks, cognitive-control systems, emotional-regulation pathways, reinforcement-learning architecture, salience networks, and adaptive behavioral regulation mechanisms.

ETIOPATHOGENIC CORE

Primary Pathogenic Theme

Repeated hallucinogen exposure alters reward processing, behavioral reinforcement systems, cognitive regulation mechanisms, and motivational priorities, resulting in persistent substance-seeking behaviors and impaired self-regulation.

Core Pathogenic Drivers

SCF FAULT ARCHITECTURE

Tier 1 — Substance Vulnerability Layer

Predisposing Factors

Potential contributors include:

• Family history of substance-use disorders
• Childhood adversity
• Trauma exposure
• Impulsivity
• Sensation-seeking traits
• Mood disorders
• Anxiety disorders
• Peer substance exposure
• Social instability
• Early substance experimentation

Psychological Vulnerabilities

Common contributors include:

• Emotional dysregulation
• Escapism tendencies
• Curiosity-driven risk-taking
• Stress sensitivity
• Identity instability
• Maladaptive coping strategies

Tier 2 — Reinforcement and Cognitive Dysregulation

Reward-System Adaptation

Individuals may experience:

• Increased salience of substance use
• Drug-related preoccupation
• Craving development
• Reinforcement learning consolidation
• Substance prioritization

Cognitive-Control Dysfunction

Manifestations may include:

Tier 3 — Hallucinogen Use Disorder Consolidation

Behavioral Symptoms

Manifestations include:

• Repeated hallucinogen use
• Escalating frequency of use
• Failed attempts to reduce consumption
• Continued use despite consequences
• Significant time devoted to obtaining or using substances
• Substance-centered lifestyle patterns

Cognitive Symptoms

Manifestations include:

• Cravings
• Drug-related preoccupation
• Impaired concentration
• Reduced decision-making quality
• Risk underestimation
• Persistent thoughts regarding substance use

Emotional Symptoms

Manifestations include:

• Emotional reliance on substances
• Mood instability
• Anxiety
• Irritability
• Psychological distress
• Reduced coping capacity

Social and Functional Symptoms

Manifestations include:

• Relationship strain
• Occupational impairment
• Academic decline
• Social withdrawal
• Reduced productivity
• Lifestyle disruption

Tier 4 — Functional and Neurobehavioral Decompensation

Potential outcomes include:

• Severe substance dependence
• Occupational dysfunction
• Educational failure
• Relationship deterioration
• Anxiety disorders
• Depressive disorders
• Persistent perceptual disturbances in some individuals
• Social instability
• Reduced quality of life
• Chronic functional impairment

MOLECULAR MULTI-OMICS PATHOGENESIS MAP

Genomics

Potential susceptibility systems:

• Addiction-related genes
• Reward-processing pathways
• Stress-response regulators
• Impulse-control genes
• Neuroplasticity pathways

Epigenomics

Potential alterations:

• Substance-exposure adaptations
• Stress-related methylation signatures
• Reward-system remodeling
• Addiction-associated regulatory modifications

Transcriptomics

Potential dysregulated pathways:

• Reward-learning networks
• Behavioral-reinforcement systems
• Cognitive-control pathways
• Stress-response mechanisms

Proteomics

Potential abnormalities:

• Neuroplasticity mediators
• Reward-signaling proteins
• Synaptic-regulation factors
• Stress-response proteins

Metabolomics

Potential disturbances:

• Serotonergic signaling alterations
• Dopaminergic pathway adaptations
• Cortisol dysregulation
• Neuroenergetic imbalance
• Neurotransmitter metabolism alterations

Interactomics

Potential network dysfunction:

• Craving–reinforcement loops
• Substance-seeking maintenance pathways
• Stress–relapse amplification cascades
• Reward–behavior consolidation networks

Connectomics

Frequently implicated neural circuits:

Adapted from SCF multi-omic pathophysiology reconstruction principles.

PATHOGENESIS FLOW (SCF LOGIC)

Substance Exposure

↓

Psychoactive Reinforcement

↓

Reward-System Adaptation

↓

Behavioral Conditioning

↓

Craving Development

↓

Executive-Control Impairment

↓

Continued Substance Use

↓

Functional Consequences

↓

Substance Dependence Consolidation

↓

Hallucinogen Use Disorder

CLINICAL PRESENTATION

Behavioral Symptoms

• Repeated hallucinogen use
• Difficulty reducing use
• Continued use despite consequences
• Increased substance prioritization
• Excessive time devoted to substance use
• Impaired behavioral control

Cognitive Symptoms

• Cravings
• Drug-related preoccupation
• Reduced concentration
• Impaired judgment
• Risk underestimation
• Substance-centered thinking

Emotional Symptoms

• Anxiety
• Mood instability
• Irritability
• Emotional dependence
• Reduced coping abilities
• Psychological distress

Functional Symptoms

• Academic difficulties
• Occupational impairment
• Relationship strain
• Social withdrawal
• Reduced productivity
• Quality-of-life deterioration

Potential Substance-Related Complications

• Intoxication-related injuries
• High-risk behaviors
• Persistent perceptual symptoms in some individuals
• Psychological destabilization
• Exacerbation of psychiatric vulnerabilities

PATHOGENS → SYMPTOMATOLOGY → SCF FAULT TIER MAPPING

ASSOCIATED CONDITIONS

Hallucinogen Use Disorder commonly overlaps with:

• Cannabis Use Disorder
• Polysubstance Use Disorder
• Alcohol Use Disorder
• Anxiety Disorders
• Major Depressive Disorder
• Behavioral Dyscontrol Syndrome
• Compulsive Risk-Taking Disorder
• Emotional Dysregulation Syndrome
• Chronic Psychological Exhaustion
• Trauma-Related Disorders

DIAGNOSTIC CONSIDERATIONS

Core Diagnostic Features

Individuals commonly demonstrate:

• Problematic hallucinogen use pattern
• Impaired control over consumption
• Persistent craving or urges
• Continued use despite harm
• Functional impairment
• Clinically significant distress

Differential Considerations

SCF THERAPEUTIC MECHANISMS

SCF-PCR PREVENTATIVE

Objectives

• Prevent escalation of substance use
• Strengthen behavioral self-regulation
• Improve resilience and coping skills
• Reduce relapse vulnerability
• Promote adaptive lifestyle functioning

SCF-PCR CURATIVE

Therapeutic Targets

Addiction Layer

• Craving reduction
• Substance-use interruption
• Reinforcement-loop disruption

Cognitive Layer

• Decision-making improvement
• Risk-awareness enhancement
• Executive-control restoration

Emotional Layer

• Emotional-regulation enhancement
• Stress-management optimization
• Adaptive coping development

Behavioral Layer

• Trigger management
• Relapse prevention
• Behavioral restructuring

Social Layer

• Recovery-support development
• Relationship stabilization
• Community reintegration

SCF-PCR RESTORATIVE

Functional Restoration Goals

• Sustained recovery
• Improved psychological health
• Occupational stability
• Social functioning
• Quality-of-life restoration
• Long-term resilience

CURRENT EVIDENCE-BASED TREATMENT APPROACHES

Psychological and Behavioral Interventions

Primary Approaches

• Cognitive Behavioral Therapy (CBT)
• Motivational Enhancement Therapy
• Motivational Interviewing
• Relapse Prevention Programs
• Contingency Management
• Group Recovery Programs

Therapeutic Objectives

• Reduce substance use
• Improve self-control
• Strengthen recovery skills
• Prevent relapse

Supportive Interventions

• Recovery-support networks
• Family interventions
• Stress-management training
• Lifestyle rehabilitation
• Occupational support
• Peer-support programs

Pharmacologic Considerations

There is currently no universally approved medication specifically indicated for Hallucinogen Use Disorder.

Pharmacologic management may be considered for:

• Co-occurring anxiety disorders
• Depressive disorders
• Sleep disturbances
• Other psychiatric comorbidities

Treatment should be individualized according to symptom profile and clinical needs.

PROGNOSIS

Prognosis is influenced by:

• Severity of substance use
• Duration of use
• Psychiatric comorbidity burden
• Social support availability
• Treatment engagement
• Recovery-environment stability
• Stress exposure
• Motivation for change

Many individuals achieve meaningful recovery through evidence-based behavioral treatment, supportive recovery environments, relapse-prevention strategies, and long-term psychosocial support.

SCF THERAPEUTIC MECHANISMS (SCF-PCR BRAID)

Preventative

• Early intervention
• Substance-risk education
• Resilience development
• Coping-skill enhancement

Curative

• Substance-use reduction
• Craving management
• Behavioral restructuring
• Recovery-skill development

Restorative

• Functional recovery
• Social reintegration
• Psychological wellbeing
• Long-term recovery maintenance

PROJECT RHENOVA — INTEGRATION PATHWAYS

Research Axis 1

Multi-omic characterization of hallucinogen-use vulnerability and addiction phenotypes.

Research Axis 2

Craving, reinforcement, and recovery biomarker discovery.

Research Axis 3

Reward-network and executive-control connectomics mapping.

Research Axis 4

Substance reinforcement–stress–relapse interaction pathway modeling.

Research Axis 5

Precision recovery frameworks for hallucinogen-related substance-use disorders.

NEXT STRATEGIC RESEARCH PATHWAYS

1. Hallucinogen Use Disorder biomarker discovery programs.
2. Reward-system neurobiology investigations of hallucinogen dependence.
3. Addiction-network connectomics studies.
4. Craving-generation and relapse pathway characterization research.
5. Neuroplasticity mechanisms underlying addiction progression and recovery.
6. Digital phenotyping of substance-use trajectories.
7. AI-assisted relapse-risk prediction systems.
8. Precision treatment-response biomarker development.
9. Comorbidity interaction research across addiction and psychiatric disorders.
10. Functional outcome endpoint development for Hallucinogen Use Disorder prevention, treatment, and rehabilitation.

INDEX — SCF-RDOS-HUD-001

Registry Code: SCF-RDOS-HUD-001

Indication: Hallucinogen Use Disorder

Domain: Substance-Related and Addictive Disorders

Framework Version: SCF-RDOS Neuropsychiatric & Addiction Disorders Registry v1.0

Classification Tier: Behavioral Addiction / Substance Use Spectrum

Research Status: Translational Characterization Candidate

Document Type: SCF Pathophysiology and Therapeutic Development Blueprint

Registry Position: HUD-001-2026